Key Points
- Director John Childs sold 100,000 Veradermics shares at an average price of $107.12, generating $10.712 million. His remaining stake fell by 34% to 194,117 shares.
- Veradermics reported quarterly EPS of -$0.58, in line with analyst expectations, while analysts project full-year EPS of -$2.78.
- Analyst sentiment remains broadly positive, with seven Buy ratings, one Hold, and one Sell; the stock has a “Moderate Buy” consensus and a $153 average price target.
Veradermics, Incorporated (NYSE:MANE - Get Free Report) Director John Childs sold 100,000 shares of Veradermics stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a total transaction of $10,712,000.00. Following the sale, the director owned 194,117 shares in the company, valued at $20,793,813.04. This represents a 34.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Veradermics Price Performance
Shares of Veradermics stock opened at $113.18 on Friday. Veradermics, Incorporated has a 52-week low of $32.00 and a 52-week high of $131.24. The company has a market cap of $4.73 billion and a price-to-earnings ratio of -85.74. The firm has a fifty day simple moving average of $109.87.
Veradermics (NYSE:MANE - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.58) EPS for the quarter, hitting analysts' consensus estimates of ($0.58). As a group, sell-side analysts forecast that Veradermics, Incorporated will post -2.78 EPS for the current year.
Analyst Ratings Changes
A number of research analysts have commented on the stock. B. Riley Financial assumed coverage on shares of Veradermics in a research note on Wednesday, July 15th. They set a "buy" rating and a $170.00 price target for the company. Leerink Partners upped their price objective on Veradermics from $75.00 to $90.00 and gave the company an "outperform" rating in a research note on Wednesday, April 22nd. Needham & Company LLC upped their price objective on Veradermics from $136.00 to $164.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Jefferies Financial Group increased their target price on Veradermics from $138.00 to $182.00 and gave the stock a "buy" rating in a report on Tuesday, July 7th. Finally, UBS Group set a $170.00 target price on Veradermics in a research report on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $153.00.
View Our Latest Analysis on MANE
About Veradermics
(
Get Free Report)
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
